Center-Authored Papers

Filters: Author is Martin, P J  [Clear All Filters]
2016
Aki SZ, Inamoto Y, Carpenter PA, Storer BE, Sandmaier BM, Lee SJ, Martin PJ, Flowers MED.  2016.  Confounding factors affecting the National Institutes of Health (NIH) chronic Graft-Versus-Host Disease Organ-Specific Score and global severity.. Bone marrow transplantation. 51(10):1350-1353. Abstract
Watkins BK, Horan J, Storer B, Martin PJ, Carpenter PA, Flowers MED.  2016.  Recipient and donor age impact the risk of developing chronic GvHD in children after allogeneic hematopoietic transplant.. Bone marrow transplantation.
2015
Terakura S, Martin PJ, Shulman HM, Storer BE.  2015.  Cutaneous macrophage infiltration in acute GvHD.. Bone marrow transplantation.
2014
Castilla-Llorente C, Martin PJ, McDonald GB, Storer BE, Appelbaum FR, Deeg HJ, Mielcarek M, Shulman H, Storb R, Nash RA.  2014.  Prognostic factors and outcomes of severe gastrointestinal GVHD after allogeneic hematopoietic cell transplantation.. Bone marrow transplantation. 49(7):966-71. Abstract
Inamoto Y, Jagasia M, Wood WA, Pidala J, Palmer J, Khera N, Weisdorf D, Carpenter PA, Flowers MED, Jacobsohn D et al..  2014.  Investigator feedback about the 2005 NIH diagnostic and scoring criteria for chronic GVHD.. Bone marrow transplantation. 49(4):532-8. Abstract
2013
Newell LF, Flowers MED, Gooley TA, Milano F, Carpenter PA, Martin PJ, Delaney C.  2013.  Characteristics of chronic GVHD after cord blood transplantation.. Bone marrow transplantation. 48(10):1285-90. Abstract
Wood WA, Chai X, Weisdorf D, Martin PJ, Cutler C, Inamoto Y, Wolff D, Pavletic SZ, Pidala J, Palmer JM et al..  2013.  Comorbidity burden in patients with chronic GVHD.. Bone marrow transplantation. 48(11):1429-36. Abstract
2012
Martin PJ, Chien JW.  2012.  What we know and mostly do not know about bronchiolitis obliterans syndrome.. Bone marrow transplantation. 47(1):1-4.
2000
Press OW, Eary JF, Gooley T, Gopal AK, Liu S, Rajendran JG, Maloney DG, Petersdorf S, Bush SA, Durack LD et al..  2000.  A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas.. Blood. 96(9):2934-42. Abstract
1999
Matthews DC, Appelbaum FR, Eary JF, Fisher DR, Durack LD, Hui TE, Martin PJ, Mitchell D, Press OW, Storb R et al..  1999.  Phase I study of (131)I-anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome.. Blood. 94(4):1237-47. Abstract
1998
Liu SY, Eary JF, Petersdorf SH, Martin PJ, Maloney DG, Appelbaum FR, Matthews DC, Bush SA, Durack LD, Fisher DR et al..  1998.  Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 16(10):3270-8. Abstract
1997
Mielcarek M, Martin PJ, Torok-Storb B.  1997.  Suppression of alloantigen-induced T-cell proliferation by CD14+ cells derived from granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cells.. Blood. 89(5):1629-34. Abstract
1995
Matthews DC, Appelbaum FR, Eary JF, Fisher DR, Durack LD, Bush SA, Hui TE, Martin PJ, Mitchell D, Press OW.  1995.  Development of a marrow transplant regimen for acute leukemia using targeted hematopoietic irradiation delivered by 131I-labeled anti-CD45 antibody, combined with cyclophosphamide and total body irradiation.. Blood. 85(4):1122-31. Abstract
Press OW, Eary JF, Appelbaum FR, Martin PJ, Nelp WB, Glenn S, Fisher DR, Porter B, Matthews DC, Gooley T.  1995.  Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas.. Lancet. 346(8971):336-40. Abstract
1993
Press OW, Eary JF, Appelbaum FR, Martin PJ, Badger CC, Nelp WB, Glenn S, Butchko G, Fisher D, Porter B.  1993.  Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support.. The New England journal of medicine. 329(17):1219-24. Abstract
Press OW, Eary J, Badger CC, Appelbaum FR, Wiseman G, Matthews D, Martin PJ, Bernstein ID.  1993.  High-dose radioimmunotherapy of lymphomas.. Cancer treatment and research. 68:13-22.
1992
Appelbaum FR, Matthews DC, Eary JF, Badger CC, Kellogg M, Press OW, Martin PJ, Fisher DR, Nelp WB, Thomas ED.  1992.  The use of radiolabeled anti-CD33 antibody to augment marrow irradiation prior to marrow transplantation for acute myelogenous leukemia.. Transplantation. 54(5):829-33. Abstract
1991
Matthews DC, Appelbaum FR, Eary JF, Hui TE, Fisher DR, Martin PJ, Durack LD, Nelp WB, Press OW, Badger CC.  1991.  Radiolabeled anti-CD45 monoclonal antibodies target lymphohematopoietic tissue in the macaque.. Blood. 78(7):1864-74. Abstract
Press OW, Eary JF, Badger CC, Martin PJ, Appelbaum FR, Nelp WB, Levy R, Miller R, Fisher D, Matthews D.  1991.  Radiolabeled antibody therapy of human B cell lymphomas.. Advances in experimental medicine and biology. 303:91-6.
1990
Bernstein ID, Eary JF, Badger CC, Press OW, Appelbaum FR, Martin PJ, Krohn KA, Nelp WB, Porter B, Fisher D.  1990.  High dose radiolabeled antibody therapy of lymphoma.. Cancer research. 50(3 Suppl):1017s-1021s. Abstract
Press OW, Eary JF, Badger CC, Martin PJ, Appelbaum FR, Nelp WB, Krohn KA, Fisher D, Porter B, Thomas ED.  1990.  High-dose radioimmunotherapy of B cell lymphomas.. Frontiers of radiation therapy and oncology. 24:204-13;discussion225-7.
1989
Press OW, Farr AG, Borroz KI, Anderson SK, Martin PJ.  1989.  Endocytosis and degradation of monoclonal antibodies targeting human B-cell malignancies.. Cancer research. 49(17):4906-12. Abstract
Press OW, Eary JF, Badger CC, Martin PJ, Appelbaum FR, Levy R, Miller R, Brown S, Nelp WB, Krohn KA.  1989.  Treatment of refractory non-Hodgkin's lymphoma with radiolabeled MB-1 (anti-CD37) antibody.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 7(8):1027-38. Abstract
1988
Press OW, Martin PJ, Thorpe PE, Vitetta ES.  1988.  Ricin A-chain containing immunotoxins directed against different epitopes on the CD2 molecule differ in their ability to kill normal and malignant T cells.. Journal of immunology (Baltimore, Md. : 1950). 141(12):4410-7. Abstract
Press OW, Hansen JA, Farr A, Martin PJ.  1988.  Endocytosis and degradation of murine anti-human CD3 monoclonal antibodies by normal and malignant T-lymphocytes.. Cancer research. 48(8):2249-57. Abstract